PatentJun 2, 2026, 08:13 AM
Heron Therapeutics' CINVANTI Patents Invalidated by Court
AI Summary
Heron Therapeutics announced that the U.S. District Court for the District of Delaware ruled two of its patents for CINVANTI® (aprepitant) injectable emulsion, U.S. Patent Nos. 12,115,255 and 12,290,520, as invalid in litigation against Azurity Pharmaceuticals. The company expressed disappointment with the initial outcome but stated that the decision has no impact on any prior settlement agreements related to CINVANTI® or APONVIE®. Heron intends to vigorously appeal the decision to the United States Court of Appeals for the Federal Circuit to defend its intellectual property rights.
Key Highlights
- U.S. District Court for the District of Delaware ruled two of Heron's CINVANTI® patents invalid.
- The invalidated patents are U.S. Patent Nos. 12,115,255 and 12,290,520.
- The decision pertains to CINVANTI® (aprepitant) injectable emulsion.
- The litigation was against Azurity Pharmaceuticals, Inc.
- The court's decision does not impact any prior settlement agreements related to CINVANTI® or APONVIE®.
- Heron Therapeutics plans to appeal the decision to the United States Court of Appeals for the Federal Circuit.
- CEO Craig Collard expressed disappointment and stated the company will vigorously pursue its appeal.
Price Impact
More from HRTX